Kalos Management, Inc. Eli Lilly & CO Transaction History

Kalos Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$278.73 - $327.27 $240,265 - $282,106	862 New	862 $279,000
Q4 2019 Feb 13, 2020	SELL	$106.92 - $132.43 $2.68 Million - $3.32 Million	-25,092 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$106.79 - $116.16 $1.11 Million - $1.2 Million	-10,364 Reduced 29.23%	25,092 $2.8 Million
Q2 2019 Aug 14, 2019	BUY	$110.79 - $129.32 $821,840 - $959,295	7,418 Added 26.46%	35,456 $4.1 Million
Q1 2019 May 15, 2019	SELL	$111.31 - $131.02 $810,002 - $953,432	-7,277 Reduced 20.61%	28,038 $3.64 Million
Q4 2018 Feb 13, 2019	SELL	$105.9 - $118.64 $243,040 - $272,278	-2,295 Reduced 6.1%	35,315 $4.09 Million
Q3 2018 Nov 14, 2018	SELL	$85.86 - $107.31 $26,101 - $32,622	-304 Reduced 0.8%	37,610 $4.04 Million
Q2 2018 Aug 14, 2018	BUY	$75.7 - $86.88 $2.87 Million - $3.29 Million	37,914 New	37,914 $3.24 Million

4,011

751M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $756B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Kalos Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kalos Management, Inc. with notifications on news.